Table 2.
The natural products acting on SIRT1 in hemorrhagic stroke.
| Studied drugs | Mechanisms | Classes of action | Animal models | Reference |
|---|---|---|---|---|
| Adiponectin (APN) | Activating SIRT1/PGC-1α | Antioxidation | Glutamate- (Glu-) induced excitotoxicity in mouse HT22 hippocampal cells | Yue et al. [53] |
| Salvianolic acid B (SalB) | Downregulation of Ac-FOXO1 | Anti-neuroinflammation and antioxidation | Middle cerebral artery occlusion (MCAO) model | Lv et al. [109] |
| Alpha-lipoic acid | Activating SIRT1/PGC-1α pathway | Antioxidation | MCAO | Fu et al. [186] |
| Astragaloside IV (AS-IV) | Activating Sirt1/Mapt pathway | Antioxidation | MCAO | Shi et al. [85] |
| Arctigenin (ARC) | NLRP3 inflammasome | Anti-neuroinflammation | MCAO | Zhang et al. [142] |
| Quercetin | Activating SIRT1/Nrf2 pathway | Antioxidation | MCAO | Yang et al. [177] |
| Momordica charantia polysaccharides (MCPs) | Activating SIRT1/β-catenin pathway | Antioxidation | MCAO | Hu et al. [179] |
| Icariin (ICA) | Activating SIRT1/PGC-1α pathway | Antioxidation | MCAO | Zhu et al. [180] |
| Kaempferol (KFL) | Activating SIRT1/P66shc pathway | Antioxidation | Oxygen and glucose deprivation (OGD) | Zhou and Li [182] |
| Calycosin-7-O-β-D-glucoside (CG) | Activating SIRT1/FOXO1/PGC-1α pathway | Antioxidation | OGD | Yan et al. [58] |
| Notoginseng leaf triterpenes (PNGL) | Activating SIRT1/2/3-Foxo3a-MnSOD/PGC-1α pathways | Antioxidation | OGD | Xie et al. [183] |
| Cycloastragenol (CAG) | Suppression of SIRT1/NF-κB activation | Anti-neuroinflammation | MCAO | Li et al. [185] |
| Piceatannol | Activating Sirt1/FoxO1 pathway | Antioxidation | MCAO | Wang et al. [168] |